SK Hynix spins off Solidigm for US IPO: Goldman Sachs and Morgan Stanley lead underwriting, $10 billions fundraising focuses on AI storage
SK Hynix has finalized the underwriting lineup for the U.S. IPO of its NAND flash memory subsidiary, Solidigm, choosing Goldman Sachs and Morgan Stanley as lead underwriters. The fundraising amount is approximately 10 billions USD. This marks the first time since SK Hynix acquired Intel's NAND and SSD business and established Solidigm that a clear independent capital operation path has been defined for this asset.
On October 7, according to Bloomberg, SK Hynix has selected Goldman Sachs and Morgan Stanley as the lead underwriters for Solidigm’s US IPO, which could raise about 10 billion USD. Following SK Hynix’s own record-breaking Nasdaq listing this July that raised 26.5 billion USD, the Korean memory giant is once again bringing its assets to the US public market.
This spin-off means Solidigm will be independently priced on the US stock market, focusing on AI-driven enterprise storage demand, providing investors with a publicly listed target to independently observe NAND business performance.
Against the backdrop of rising NAND prices and expanding enterprise storage demand from AI data centers, Solidigm’s independent listing becomes the latest step in the securitization of memory assets.
SK Hynix previously completed the acquisition of Intel’s NAND and SSD business and established its subsidiary Solidigm, but the capital operation path for this subsidiary had remained unclear. The selection of Goldman Sachs and Morgan Stanley as lead underwriters to push for its independent US listing marks SK Hynix’s formal move to bring its NAND business to the public market.
The core rationale for Solidigm’s independent listing is to obtain a higher valuation as an independent entity and to focus on AI-driven enterprise storage demand. NAND differs significantly from SK Hynix’s main products, HBM and DRAM, in terms of technology paths and customer structure. After listing independently, Solidigm can establish its own financing channels and directly present its enterprise storage narrative to US investors.
NAND Upcycle and the Race with Kioxia
The timing of Solidigm’s listing coincides with a NAND price upcycle.
According to TrendForce data, in Q2 2026 NAND flash prices increased by 55% to 60% quarter-on-quarter, and are expected to rise another 10% to 15% in Q3. Meanwhile, Kioxia, a Toshiba subsidiary, is also preparing for a US listing, with both leading giants in the NAND sector advancing their capital market moves simultaneously.
SK Hynix itself set a record for foreign companies’ IPOs in the US with 26.5 billion USD raised. Whether Solidigm can replicate its parent company’s market enthusiasm by raising about 10 billion USD will be the first window to observe whether the AI storage narrative can support an independent NAND valuation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fed Governor Waller leaves room for hawkishness: More rate hikes are needed to support inflation decline, not necessarily on a monthly basis.
Federal Reserve Governor Waller stated that if the data meets expectations, there will be further interest rate hikes. The core PCE year-on-year rate at 3% is still too high, and the recent monetary policy focus remains on fighting inflation.
Updated: Viatris will acquire pain therapy manufacturer Pacira BioSciences for 1.65 billions dollars.
The second paragraph adds stock information, while the fifth, eighth, and ninth paragraphs provide additional details. Background information is supplemented in the sixth, seventh, tenth, and eleventh paragraphs. Reuters, October 8 – Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences (PCRX.O) in an all-cash deal worth $1.65 billions, adding two non-opioid painkillers to its portfolio, the companies said on Thursday. Viatris will acquire Pacira at $36.50 per share, representing a 44.8% premium to the latest closing price. Pacira’s stock rose by 44% in premarket trading. Pacira’s non-opioid painkillers, Exparel and Zilretta, generated sales in 2025 of $575.1 millions and $116.6 millions respectively. Exparel is used to relieve acute pain after surgery, and Zilretta is used to treat pain associated with knee osteoarthritis. Viatris stated it expects to expand the reach of these products in selected target markets. Viatris CEO Scott Smith stated, “the addition of these medications creates a synergy with our rapid-acting meloxicam market opportunities, positioning us as a leader in non-opioid pain management.” The US Food and Drug Administration (FDA) is expected to make a decision by December 27 on the approval application for rapid-acting meloxicam for the treatment of moderate to severe acute pain. Viatris plans to finance the acquisition primarily with idle cash, and the remainder through short-term borrowing. The company noted the deal will have minimal impact on its total leverage ratio. In August, Viatris (link) raised its annual adjusted profit forecast, counting on strong brand drug sales and growth in the Chinese market. The pharmaceutical company had previously faced (link) production setbacks in its Indian operations, including a fire at its Nashik plant in western India and increased competition in the generic drug market, raising concerns about the resilience and growth of its core business. The company stated the transaction is expected to close by the end of 2026 and will immediately enhance Viatris’s financial guidance metrics. (For non-native English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack necessary context, Reuters does not guarantee their accuracy and provides them for convenience only. Reuters accepts no liability for any damage or loss caused by the use of automated translation.)
Oppenheimer Adjusts Acuity Price Target to $415 From $440, Maintains Outperform Rating
08:51 AM EDT, 10/08/2026 (MT Newswires) -- Acuity Brands (AYI) has an average rating of overweight and mean price target of $400.57, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
BUZZ-Pacira BioSciences stock surges on Viatris' $1.65 billion acquisition deal
On October 8, Pacira BioSciences (PCRX.O) shares rose 44% in pre-market trading to $36.30 as Viatris (VTRS.O) announced it will acquire Pacira BioSciences for $1.65 billion in cash, at a price of $36.50 per share. This offer represents a premium of approximately 44.8% over Pacira's last closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris’ product portfolio. Both parties expect the deal to be completed by the end of 2026. As of the previous trading day’s close, PCRX was down 2.6% year-to-date.
Crypto prices
More
